Catalyst News and Research

RSS

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

The Muscular Dystrophy Association (MDA), headquartered in Tucson, Ariz., and Friends of FSH Research (FFSHR), based in Kirkland, Wash., has jointly awarded a two-year, $200,000 grant to Dr. Joel Chamberlain, a research assistant professor of medical genetics at the University of Washington. The grant, equally funded by the two organizations, will enable the laboratory led by Dr. Chamberlain to study RNA interference as an investigative and therapeutic tool for facioscapulohumeral muscular dystrophy.

7 Apr 2010

BioCenter: Launch point for biomedical innovation in North Texas

BioCenter at Southwestern Medical District offers a springboard to drive biomedical innovation in North Texas to business operations, from earliest stage startups exploring bold new ideas to established companies needing an entire custom-designed floor to bring products to fruition.

3 Apr 2010

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.

1 Apr 2010

DATATRAK International, NTT DATA to sell Enterprise Transfer services within Japanese market

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced NTT DATA, its strategic partner in Japan, has signed its first Enterprise Transfer client.

1 Apr 2010

Derma Sciences reports 69% increase in Advanced Wound Care sales for fourth-quarter 2009

Derma Sciences, Inc., a specialty medical device/pharmaceutical company focused on advanced wound care, reported financial and operating results today for the three months and fiscal year ended December 31, 2009.

1 Apr 2010

Small businesses prepare for health reform changes

As business owners across the country consider the newly enacted health overhaul, "they're looking to Massachusetts for harbingers of things to come. Massachusetts' law, which mandates near-universal coverage and requires that businesses with 11 or more workers offer insurance, provided the blueprint for the health law signed by President Barack Obama.

1 Apr 2010

Novo Nordisk BlueSheet launched to provide information on diabetes and chronic disease

Novo Nordisk, a global healthcare company and leader in diabetes care, today announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.

30 Mar 2010

UCSF approach may one day be used to create new periods of plasticity in human brain

UCSF scientists report that they were able to prompt a new period of "plasticity," or capacity for change, in the neural circuitry of the visual cortex of juvenile mice. The approach, they say, might some day be used to create new periods of plasticity in the human brain that would allow for the repair of neural circuits following injury or disease.

27 Mar 2010

CTMS solutions provider TranSenda International acquired by BioClinica

BioClinica™, Inc.,, a global provider of clinical trial management services, today announced its acquisition of substantially all of the assets of privately held TranSenda International, LLC. Headquartered in Bellevue, WA, TranSenda is a provider of clinical trial management software (CTMS) solutions and is a Microsoft Gold Certified Partner.

From Clario 26 Mar 2010

Nanobotmodels animates future DNA repairing process

Nanobotmodels Company made detail animation of DNA-repair process using nanomechanical robot. You can see all stages of repair in this animation, based on DNA-nanorobot model.

22 Mar 2010

U.S to face potential outbreak of hyperinflation by 2015

The National Inflation Association - http://inflation.us - today issued a warning to all Americans of a potential outbreak of hyperinflation in the U.S. by year 2015 caused primarily by the healthcare bill and rising interest payments on our national debt.

20 Mar 2010

W. R. Grace earns GMP certification

W. R. Grace & Co.has earned Good Manufacturing Practices certification of its facility in Baltimore, Maryland. The certification encompasses Grace’s Quality Management System that includes the standards, procedures and manufacturing operations used by the company in the production of pharmaceutical grade silica (commonly marketed by Grace under the SYLOID® brand name).

19 Mar 2010

Kaiser Permanente study: Snapshot of the prevalence of extreme obesity in younger children

Extreme obesity is affecting more children at younger ages, with 12 percent of black teenage girls, 11.2 percent of Hispanic teenage boys, 7.3 percent of boys and 5.5 percent of girls now classified as extremely obese, according to a Kaiser Permanente study of 710,949 children and teens that appears online in the Journal of Pediatrics.

19 Mar 2010

Nanobotmodels Company offer vision of future DNA and cell-repair techniques

Developments in nanotechnology and nanorobotics are opening up the prospects for nanomedicine and regenerative medicine where informatics and DNA computing can become the catalysts enabling health care applications at sub-molecular or atomic scales. While nanomedicine promises a new exciting frontier for clinical practice and biomedical research, issues involving cost-effectiveness studies, clinical trials and toxicity assays, drug delivery methods, and the implementation of new personalized therapies still remain challenging.

18 Mar 2010

Genes allowing opium poppy to make codeine and morphine discovered

Researchers at the University of Calgary have discovered the unique genes that allow the opium poppy to make codeine and morphine, thus opening doors to alternate methods of producing these effective painkillers either by manufacturing them in a lab or controlling the production of these compounds in the plant.

18 Mar 2010

Haiti should have final say over rebuilding, Preval says

In an interview with Reuters, Haitian President Rene Preval on Tuesday said that the U.S. State Department Human Rights report, which says corruption is "widespread in all … levels of government" in Haiti, is "arrogant" and that Haiti should have the final say in approving plans to rebuild the country after the January earthquake, the news agency reports.

18 Mar 2010

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Ipsen, a global biotechnology specialty care group, and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.

12 Mar 2010

Regence acquires assets of Kinetix Living

As part of its continued focus on developing programs designed to meet employers' needs, Regence has acquired the assets of Kinetix Living Corp., a Seattle-based company that provides customized health and nutrition programs to corporate clients and individuals throughout the country.

11 Mar 2010

Viatronix V3D-Colon software used for the President's colon cancer screening exam

Viatronix Incorporated, a Stony Brook, New York, based company announced that its V3D-Colon software is used at the National Naval Medical Center where the President's annual physical was done. "Our software is being utilized at several DOD facilities since the landmark Virtual Colonoscopy clinical trial published in the New England Journal of Medicine back in December 2003," said Zaffar Hayat, President of Viatronix Incorporated.

9 Mar 2010

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone.

9 Mar 2010

Catalyst News and Research

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

BioCenter: Launch point for biomedical innovation in North Texas

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

DATATRAK International, NTT DATA to sell Enterprise Transfer services within Japanese market

Derma Sciences reports 69% increase in Advanced Wound Care sales for fourth-quarter 2009

Small businesses prepare for health reform changes

Novo Nordisk BlueSheet launched to provide information on diabetes and chronic disease

UCSF approach may one day be used to create new periods of plasticity in human brain

CTMS solutions provider TranSenda International acquired by BioClinica

Nanobotmodels animates future DNA repairing process

U.S to face potential outbreak of hyperinflation by 2015

W. R. Grace earns GMP certification

Kaiser Permanente study: Snapshot of the prevalence of extreme obesity in younger children

Nanobotmodels Company offer vision of future DNA and cell-repair techniques

Genes allowing opium poppy to make codeine and morphine discovered

Haiti should have final say over rebuilding, Preval says

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Regence acquires assets of Kinetix Living

Viatronix V3D-Colon software used for the President's colon cancer screening exam

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News